
Innoviva, Inc. (NASDAQ:INVA – Free Report) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Innoviva in a note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of $2.37 for the year, up from their previous forecast of $2.30. The consensus estimate for Innoviva’s current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.30 EPS.
INVA has been the topic of several other reports. Piper Sandler initiated coverage on shares of Innoviva in a research note on Wednesday. They issued an “overweight” rating and a $29.00 target price on the stock. Weiss Ratings upgraded shares of Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a report on Monday, November 9th. Oppenheimer dropped their price target on shares of Innoviva from $35.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Wall Street Zen cut shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Zacks Research raised shares of Innoviva from a “strong sell” rating to a “hold” rating in a report on Monday, August 31st. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.
Innoviva Stock Performance
NASDAQ:INVA opened at $18.40 on Tuesday. The firm has a market cap of $1.31 billion, a PE ratio of 9.25, a price-to-earnings-growth ratio of 2.62 and a beta of 0.38. Innoviva has a fifty-two week low of $18.23 and a fifty-two week high of $25.15. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.58 and a current ratio of 15.44. The business has a 50 day moving average price of $20.53 and a 200-day moving average price of $21.83.
Innoviva (NASDAQ:INVA – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($1.55). Innoviva had a return on equity of 22.91% and a net margin of 44.13%. The company had revenue of $106.12 million during the quarter, compared to analysts’ expectations of $115.31 million.
Institutional Trading of Innoviva
Large investors have recently added to or reduced their stakes in the stock. Chase Investment Counsel Corp purchased a new stake in Innoviva in the second quarter worth about $1,589,000. Hsbc Holdings PLC bought a new position in shares of Innoviva during the second quarter valued at approximately $843,000. Bank of America Corp DE bought a new position in shares of Innoviva during the second quarter valued at approximately $37,873,000. Baird Financial Group Inc. bought a new position in shares of Innoviva during the second quarter valued at approximately $6,231,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Innoviva by 1.7% during the first quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after purchasing an additional 76,026 shares during the last quarter. Institutional investors own 99.12% of the company’s stock.
About Innoviva
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Recommended Stories
- Five stocks we like better than Innoviva
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
